{"entity":{"id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of Toripalimab and Rituximab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","summary":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05615974 by LaNova Medicines Limited, with 139 participants planned, started 2023-01-11 and due to reach its primary completion in 2027-01-11. Interventions recorded: LM101, Toripalimab and Rituximab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05615974","url":"https://clinicaltrials.gov/study/NCT05615974"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab","rituximab"],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05615974","phase":"1/2","setting":"A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors","sponsor":"LaNova Medicines Limited","enrolled":139,"outcomes":[]},"route":"/trials/nct05615974/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}